Wells Fargo & Company MN Buys 107,486 Shares of Amphastar Pharmaceuticals Inc (AMPH)

Wells Fargo & Company MN lifted its holdings in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 156.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 176,323 shares of the company’s stock after acquiring an additional 107,486 shares during the period. Wells Fargo & Company MN owned 0.38% of Amphastar Pharmaceuticals worth $3,392,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $242,000. Municipal Employees Retirement System of Michigan raised its position in shares of Amphastar Pharmaceuticals by 58.8% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock worth $239,000 after acquiring an additional 4,960 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Amphastar Pharmaceuticals by 164.7% during the 3rd quarter. SG Americas Securities LLC now owns 16,385 shares of the company’s stock worth $293,000 after acquiring an additional 10,195 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Amphastar Pharmaceuticals by 70.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock worth $321,000 after acquiring an additional 7,401 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $400,000. 44.46% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Needham & Company LLC reissued a “buy” rating and set a $24.00 target price (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BMO Capital Markets reissued a “market perform” rating and set a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, Wells Fargo reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $21.33.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 16,598 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $19.90, for a total transaction of $330,300.20. Following the transaction, the director now owns 45,442 shares of the company’s stock, valued at $904,295.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jason B. Shandell sold 20,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total value of $388,600.00. Following the transaction, the insider now directly owns 251,372 shares in the company, valued at approximately $4,884,157.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 84,387 shares of company stock worth $1,659,763. 11.10% of the stock is currently owned by corporate insiders.

AMPH opened at $19.01 on Friday. The company has a market cap of $881.13, a price-to-earnings ratio of 61.32, a PEG ratio of 1.35 and a beta of 1.42. Amphastar Pharmaceuticals Inc has a 52 week low of $13.15 and a 52 week high of $20.45. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Monday, March 12th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. The company had revenue of $60.40 million for the quarter, compared to analyst estimates of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 earnings per share. equities analysts predict that Amphastar Pharmaceuticals Inc will post 0.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company MN Buys 107,486 Shares of Amphastar Pharmaceuticals Inc (AMPH)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3340381/wells-fargo-company-mn-buys-107486-shares-of-amphastar-pharmaceuticals-inc-amph.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

California Resources  Bond Prices Rise 1.5%
California Resources Bond Prices Rise 1.5%
eGold Hits 24 Hour Trading Volume of $0.00
eGold Hits 24 Hour Trading Volume of $0.00
Guncoin  Price Down 1.2% Over Last Week
Guncoin Price Down 1.2% Over Last Week
Critical Contrast: Cintas  and Oxford Industries
Critical Contrast: Cintas and Oxford Industries
Analyzing Swiss Re  & Torchmark
Analyzing Swiss Re & Torchmark
NICE Systems  versus Capcom  Financial Survey
NICE Systems versus Capcom Financial Survey


Leave a Reply

© 2006-2018 Ticker Report. Google+.